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Background:  Th   is experiment was performed to determine the eff  ect of polyphenolic (-)-epigallocatechin (EGCG), 
the most abundant catechin of green tea, given at reperfusion period.
Methods:  Isolated rat hearts were subjected to 30 min of regional ischemia and 2 h of reperfusion. Green tea extract 
(GT) was perfused with the following concentrations; 0, 0.5, and 1 μM (GT-O, GT-0.5, and GT-1, respectively). 
In a next experiment, hearts were assigned randomly to one of the following groups; Control, EGCG-1 (1 μM of 
EGCG), and EGCG-10 (10 μM of EGCG).  GT and EGCG were perfused for a period of 5 min before and 30 min after 
reperfusion.  For comparison of cardioprotection among groups, morphometric measurement was performed by 
2,3,5-triphenyltetrazolium chloride staning.
Results: GT 1 μM (10.3 ± 2.1%, P < 0.05) signifi  cantly reduced infarct volume as a percentage of ischemic volume 
compared to untreated hearts (27.4 ± 1.1%).  EGCG 10 μM (13.2 ± 4.0%) signifi  cantly reduced myocardial infarction 
compared to control hearts (27.2 ± 1.4%, P = 0.002).  After 2 h of reperfusion, cardiodynamic variables, including left 
ventricular developed pressure, rate-pressure produce, +dP/dtmax, and -dP/dtmin were signifi  cantly improved by 10 μM 
of EGCG compared to control hearts (P = 0.01, 0.016, 0.009, and 0.019, respectively).
Conclusions: EGCG treatment at an early reperfusion period reduces myocardial infarction and improves cardio-
dynamics in isolated rat hearts.  (Korean J Anesthesiol 2010; 58: 169-175)
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    Green tea has been known for a long time to have antioxidant 
[1], antimicrobial [2], anti-inflammatory [3], antiallergic [4], 
and anticarcinogenic [5] properties, and there is a great deal of 
interest in its bioregulatory eff  ects. Green tea has vasodilatory 
effects [6], can inhibit the development of arteriosclerosis [7], 
and there is evidence that it reduces the incidence of cardiac 
diseases [8]. 
    The main bioactive substances of green tea consist of 
(-)-epigallocatechin-3-gallate (EGCG), (-)-epigallocatechin 
(EGC), (-)-epicatechin-3-gallate (ECG), and (-)-epicatechin 
(EC)-like polyphenolic epicatechin. EGCG is the most abundant 
catechin in green tea, and has the highest biological activity [9]. 
In animal models, EGCG administration has been shown to 
inhibit the cerebral and renal ischemic injury [10,11]. 
    Recently, it has been reported that EGCG can protect the 
heart from cardiac ischemic injury [12]. However, in actual 
clinical cases, acute myocardial infarction patients already have 
cardiac ischemic injury when they are admitted to the hospital, 
and it is impossible to administer therapeutic drugs before 
an unexpected acute myocardial infarction occurs. Therefore, 
practical treatment of acute myocardial infarction would 
include administration after acute coronary artery occlusion 
or during reperfusion. The administration of EGCG during 
reperfusion has been reported to reduce cardiac reperfusion 
injury [13]; however, there have not yet been any studies on the 
extent that EGCG reduces myocardial necrosis, an indicator of 
reperfusion injury. 
    In this study, EGCG was administered to isolated rat hearts 
during coronary artery reperfusion, and the eff  ects of EGCG on 
myocardial necrosis and cardiac hemodynamics were analyzed. 
.BUFSJBMTBOE.FUIPET
*TPMBUFEIFBSUQFSGVTJPOVTJOHUIF-BOHFOEPSGG
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    Th   e proposed study was approved by the ethics committee of 
our institution. Coronary perfusion by the Langendorff   system 
with modifi  ed Krebs-Henseleit (KH) buff  er solution, containing 
118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 1.2 
KH2PO4, and 10 glucose (in mM), was performed. KH buffer 
was freshly prepared and fi  ltered through a 2.0 μm microfi  lter 
(Nalge Nunc International Corp., Rochester, NY, USA). Th  e  KH 
buffer was added to the Langendorff apparatus, and 30 min 
before the experiment, the buff  er was bubbled with 95% O2 and 
5% CO2, so that pH would be about 7.4. Th  e  Langendorff   system 
was maintained at 38
oC by a water circulation pump. 
    Male Wistar rats (Korea Taconic Co., Daegu, Korea) weighing 
280-330 g were anesthetized by an intraperitoneal injection 
of 100 mg/kg pentobarbital sodium (Entobar
⡴, Hanlim 
Pharceuticals, Yongin, Korea), and 300 IU heparin was 
also administered. After each rat was anesthetized and no 
longer responsive to noxious stimulus to the tail, a median 
thoracotomy was performed. Within 1 min of heart removal, the 
heart was immediately connected to the Langendorff system 
via the aorta, and perfused with modified KH buffer solution, 
allowing for coronary flow. The perfusion pressure was set at 
100 cmH2O above the heart. 
    Drainage of coronary perfusate from the right side of the heart 
was collected in a graduated cylinder to measure coronary 
perfusion. To measure ventricular function, a balloon was 
inserted into the left ventricle (LV) through the left atrium. Th  e 
balloon was coupled to a graded threaded micro-syringe and 
balloon volume was adjusted to give a left ventricular end-
diastolic pressure (LVEDP) of 5-10 mmHg at the beginning of 
the experiment. Th   e left ventricular developed pressure (LVDP) 
was calculated from the diff  erence between the left ventricular 
systolic pressure (LVSP) and LVEDP. Th   e rate-pressure product 
(RPP) was calculated by multiplying the heart rate by the LVDP. 
Hemodynamic parameters, including +dP/dtmax and -dP/dtmin, 
were determined using an MP150 pressure transducer (BioPac 
Systems, Santa Barbara, CA, USA).
*OEVDJOHSFHJPOBMJTDIFNJB
    Ischemia was induced after the heart had been connected 
to the Langendorff   system and a minimum of 30 min of stabi-
li  zation had elapsed. To induce regional ischemia, a 6-0 
polypropylene suture was looped around the proximal segment 
of the left coronary artery, and both ends of the suture were 
threaded through a 1 cm PE50 tube to form a snare loop. 
Ischemia was triggered by pulling the thread of the snare and 
blocking coronary artery flow. Reperfusion was induced by 
relaxing the snare. After reperfusion, if ventricular fibrillation 
(VF) occurred, there was usually spontaneous reversion to 
normal sinus rhythm within 30 sec. If the duration of VF was 
longer than 30 sec, the heart was treated with finger flick 
cardioversion until a perfusing rhythm was obtained. 
5FTUTVCTUBODFT
    Green tea extracts were made using dried commercial green 
tea leaves (Boseung green tea Myeongga, Gwangju, Korea). 
Ten milliliters of water containing 0.2 g green tea were heated 
to 60
oC and stirred for 5 min. Th   e leaves were then removed by 
fi  ltering, and the solution was freeze-dried to obtain the green 
tea extract (GT) used in the experiment. GT and EGCG (Sigma-
Aldrich Chemical Co., St. Louis, MO, USA) were each dissolved 171 www.ekja.org
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in distilled water to make less than 2.5 mM stock solutions. Th  e 
test stock solutions were stored at 4
oC and diluted on the day of 
the experiment with KH buff  er to the fi  nal concentrations. 
5FTUQSPUPDPMT
    The duration of all episodes of regional ischemia induced 
in isolated hearts was 30 min and reperfusion was performed 
for 2 h. There were 2 experiments, and hearts were randomly 
assigned to 3 groups for each experiment. For each experiment, 
either GT or EGCG were administered 5 min before coronary 
reperfusion to 30 min after reperfusion for a total of 35 min. 
    Th  e  fi  rst experiment was to determine the eff  ects of green tea 
itself, which is not a pure epicatechin. GT at 0.5 μM (GT-0.5, 
n = 7) and 1 μM (GT-1, n = 8) was administered to isolated rat 
hearts. After the hearts had undergone 2 h of reperfusion, the 
myocardial infarction was compared to the control group where 
GT was not administered (GT-0, n = 8).
    Th   e second experiment was to determine the eff  ects of EGCG, 
the main component of green tea. EGCG at 1 μM (EGCG-1, n = 
8) and 10 μM (EGCG-10, n = 8) was administered as described, 
and the myocardial infarction was then compared to the control 
group where EGCG was not administered (EGCG-0, n = 9). 
Th   ere were no diff  erences in the body weight and heart weight 
among the groups (Table 1).
.FBTVSFNFOUPGBSFBBUSJTLBOEBSFBPGOFDSPTJT
    Measurements of the areas at risk (AR) and areas of necrosis 
(AN) were performed in the same manner as in our previous 
study [14]. After 2 h of reperfusion, the snare around the left 
coronary artery was reoccluded, and 3 mL of diluted fl  uorescent 
polymer microspheres (Duke Scientific Corp., Palo Alto, CA, 
USA) were slowly infused into the aorta. Th   e hearts were then 
removed from the Langendorff   system, drained, and weighed. 
They were then frozen for 1-3 h at -20
oC. An acrylic rodent 
heart matrix (Zivic Instruments, Pittsburgh, PA, USA) was used 
to make 2 mm transverse sections. The sections were soaked 
for 20 min at 37
oC in 1% 2,3,5-triphenyltetrazolium chloride 
(TTC). Colored viable tissue by TTC was distinguished from the 
noncolored area of myocardial necrosis using 10% formalin. 
For each LV, AR, and AN, the volume (cm
3) was calculated by 
multiplying the area by the width of each specimen (2 mm). 
The area of myocardial necrosis was defined as AN/AR. All 
measurements were performed in a blinded fashion. There 
were no diff  erences in the volumes of LV, AR, or AR/LV values 
among the groups (Table 1). 
4UBUJTUJDBMBOBMZTJT
    The means ± S.E. were determined for the data. One-way 
ANOVA, as well as least significant difference tests for later 
verifi  cation, were performed. Values of P < 0.05 were considered 
to be statistically signifi  cant. Data analysis was performed using 
SPSS for Windows, version 12.0.
3FTVMUT
    A total of 51 rat hearts were used in the experiments. Th  ree 
hearts were excluded from analysis; 1 heart had an LVDP less 
than 80 mmHg and 2 hearts had continuous arrhythmias during 
the stabilization period. Therefore the results of 48 rat hearts 
Table 1. Body Weight, Heart Weight, and Morphometric Data
 Group Body weight (gm) Heart weight (gm) LV volume (cm
3) AR volume (cm
3) AR/LV (%) AN volume (cm
3)
 EGCG-0 303.1 ± 6.2 1.43 ± 0.05 0.500 ± 0.022 0.289 ± 0.014 58.2 ± 2.9 0.078 ± 0.004
 EGCG-1 301.6 ± 9.3 1.43 ± 0.05 0.496 ± 0.042 0.282 ± 0.022 57.8 ± 3.8 0.059 ± 0.010
 EGCG-10 312.5 ± 5.5 1.43 ± 0.04 0.506 ± 0.029 0.295 ± 0.028 58.2 ± 4.5 0.043 ± 0.014*
Values are mean ± SEM. EGCG: polyphenol (-)-epigallocatechin gallate. EGCG-0, EGCG-1, and EGCG-10: 0, 1, and 10 μM of EGCG, respective-
ly. LV: left ventricle, AR: area at risk, AN: area of necrosis. Th   ere were no signifi  cant diff  erences in body weight, heart weight, volumes of LV, AR, 
and AR/LV among groups. *P < 0.001 vs. EGCG-0.
Fig. 1. Area of necrosis (AN) as percentage of area at risk (AR) as 
evaluated by triphenyltetrazolium chloride staining following 30 min 
regional ischemia and 2 hrs reperfusion in isolated rat heart model. 
GT 1 μM treated hearts (GT-1) significantly decrease AN/AR com-
pared to GT-untreated hearts (GT-0) and GT 0.5 μM treated hearts 
(GT-0.5). Values are expressed as mean ± SEM. *P < 0.001 vs. GT-0, 
†P < 0.001 vs. GT-0.5.172 www.ekja.org
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were compared. 
    In the GT experiment, the AN/AR value for group GT-0.5 was 
26.0 ± 1.2% and for group GT-0 was 27.4 ± 1.1%. Th   ere was no 
signifi  cant diff  erence. However, the AN/AR for group GT-1 was 
10.3 ± 2.1%, which was significantly lower than either group 
GT-0 or GT-0.5 (P < 0.001) (Fig. 1). 
    In the EGCG experiment, 3 hearts from each of the 3 groups 
developed VF immediately after reperfusion, but immediately 
reverted to normal sinus rhythm. There were no significant 
di  fferences in the hemodynamic indicators, LVDP, RPP, +dP/
dtmax, and -dP/dtmin during the stabilization period (Table 2). 
Hemodynamic recoveries in terms of percent changes measured 
during stabilization and 2 h after reperfusion were determined 
in the EGCG groups. The percent change of LVDP for group 
EGCG-0 and group EGCG-1 were 42.8 ± 7.0% and 48.0 ± 3.3%, 
respectively, and there was no significant difference between 
the two groups. However the LVDP for group EGCG-10 was 
72.0 ± 10.5%, which was signifi  cantly higher than the LVDP of 
Table 2. Baseline Coronary Flow and Cardiodynamic Data
 Group
CF
(ml/min)
HR
(beats/min)
LVDP
(mmHg)
RPP
(mmHg/min/10
3)
+dP/dtmax
(mmHg/s/10
3) 
-dP/dtmin
(mmHg/s/10
3)
 EGCG-0 12.9 ± 0.2 281.0 ± 8.8 115.9 ± 11.3 34.0 ± 2.9 2.4 ± 0.1 -2.4 ± 0.2
 EGCG-1 14.0 ± 0.5 285.4 ± 8.4 122.5 ± 9.0 34.8 ± 2.6 2.4 ± 0.1 -2.5 ± 0.1
 EGCG-10 13.6 ± 0.6 299.4 ± 7.2 114.4 ± 9.0 34.4 ± 3.1 2.5 ± 0.2 -2.4 ± 0.2
Values are mean ± SEM. EGCG: polyphenol (-)-epigallocatechin gallate. EGCG-0, EGCG-1, and EGCG-10: 0 , 1, and 10 μM of EGCG, respectively. 
CF: coronary fl  ow, HR: heart rate, LVDP: left ventricular developed pressure, RPP: rate-pressure product. +dP/dtmax: maximum positive left 
ventricular pressure derivative, -dP/dtmin: minimum negative left ventricular pressure derivative. Th   ere were no diff  erences in baseline CF and 
cardiodynamics among groups.
Fig. 2. Recovery of the left ventricular developed pressure (LVDP), rate-pressure product (RPP), and maximum (+dP/dtmax) and minimum 
(-dP/dtmin) of fi  rst derivative of left ventricular pressure after 2 hrs of reperfusion in isolated rat hearts. Rat hearts are treated 1 (EGCG-1) or 10 μM (EGCG-
10) of polyphenol (-)-epigallocatechin gallate (EGCG). Values are expressed as mean ± SEM. *P < 0.05 vs. EGCG-untreated hearts (EGCG-0), 
†P 
< 0.05 vs. EGCG-1.173 www.ekja.org
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either group EGCG-0 or group EGCG-1 (P = 0.01, P = 0.036, 
respectively) (Fig. 2). Th   e RPP for group EGCG-0 was 38.8 ± 7.9%; 
for group EGCG-1 was 46.1 ± 3.6%; and for group EGCG-10 
was 63.9 ± 9.9%, which was signifi  cantly higher than the RPP in 
group EGCG-0 (P = 0.016). 
    Th  e  +dP/dtmax for group EGCG-0 was 44.1 ± 6.8%; for group 
EGCG-1 was 49.1 ± 3.8%; and for group EGCG-10 was 73.9 ± 
10.4%, which was significantly higher than the +dP/dtmax in 
groups EGCG-0 and EGCG-1 (P = 0.009, P = 0.029, respectively). 
The -dP/dtmin for group EGCG-0 was 40.2 ± 4.6%; for group 
EGCG-1 was 46.7 ± 2.4%; and for group EGCG-10 was 59.4 ± 
7.9%, which was significantly higher than the -dP/dtmin for 
group EGCG-0 (P = 0.019). 
    For groups EGCG-0, EGCG-1, EGCG-10, the AR/LV values 
were 58.2 ± 2.9%, 57.8 ± 3.8%, and 58.2 ± 4.5%, respectively. 
Th   ere were no signifi  cant diff  erences among the groups in the 
development of regional ischemia in the LV (Fig. 3). The AN/
AR value for group EGCG-0 was 27.2 ± 1.4%; for group EGCG-1 
was 20.3 ± 2.9%; and for group EGCG-10 was 13.2 ± 4.0%, which 
was signifi  cantly lower compared to group EGCG-0 (P = 0.002). 
The AN/LV values for groups EGCG-0, EGCG-1, and EGCG-
10 were 15.9 ± 1.2%, 12.0 ± 2.3%, and 8.7 ± 3.1%, respectively. 
Compared to group EGCG-0, the AN/LV in group EGCG-10 was 
signifi  csantly lower (P = 0.028). 
%JTDVTTJPO
      GT of 1 μM administered during reperfusion in isolated rat 
hearts eff  ectively reduced post-reperfusion myocardial necrosis. 
Ten μM of EGCG, the most abundant catechin in green tea, 
eff  ectively reduced post-reperfusion myocardial necrosis, and 
improved cardiac hemodynamics, namely the recoveries of 
LVDP, RPP, +dP/dtmax and -dP/dtmin. 
      Townsend et al. [12] first reported that 100 μM of EGCG 
administered during ischemia successfully reduced myocardial 
necrosis and prevented ischemic injury in isolated rat hearts. 
The effects of EGCG administered during reperfusion were 
first reported by Aneja et al. [13]. In an in vivo experiment, 
EGCG administered during reperfusion caused a decrease 
in myeloperoxidase activity, which is a marker of neutrophil 
accumulation, an indicator of infl  ammatory response. Th  ey  also 
reported that EGCG reduced plasma creatine phosphokinase 
activity. In cardiac tissue stained with hematoxylin and eosin, 
heart tissue trauma and necrosis were decreased in rats 
receiving EGCG. In the presented study, in which TTC stain was 
used to measure the degree of myocardial necrosis, 10 μM EGCG 
administered during reperfusion caused significant decreases 
in AN/AR and AN/LV values compared to other groups. . 
    Although 1 μM of green tea extract was shown to eff  ectively 
decrease myocardial necrosis, 1 μM EGCG had no eff  ect in reducing 
myocardial necrosis in this study. However, 10 μM EGCG was 
eff  ective. Although the exact reason for this result is not known, 
there are other catechins besides EGCG in green tea, such 
as EGC, ECG, and EC, which may also have cardioprotective 
effects. The discovery that EGCG has inotropric effects on 
isolated rat hearts supports this possibility. It has been reported 
that when green tea leaves are heated, the epimerization of 
EGCG produces (-)-gallocathechin-3-gallate (GCG), which like 
EGCG, protects the heart after reperfusion [16]. This may be 
why 1 μM green tea reduced myocardial necrosis, even though 
in the present study, 1 μM EGCG had no eff  ect. Further research 
is required to resolve this issue. 
    Aneja et al. [13] has reported that when they administered 
EGCG during reperfusion, the RPP measured after reperfusion 
was not different between the groups where EGCG had been 
administered and where it had not been. In the present study, 
however, the RPP in the group in which 10 μM EGCG was 
administered, was signifi  cantly higher after 2 h of reperfusion 
compared to the group in which EGCG had not been admini-
stered. One reason for difference in results may be due to 
diff  erences in methods of calculation. Aneja et al. [13] calculated 
the RPP using the product of the mean arterial pulse pressure 
and the heart rate; whereas the authors of this study used 
the product of LVDP and the heart rate. After reperfusion, 
compared to the other groups, in the group administered 10 μM 
EGCG, the LVSP was restored, and LVEDP decreased. This 
increased LVDP recovery, which triggered RPP recovery. Other 
reasons why the RPP results of the present study may differ 
from the RPP results of Aneja et al. [13] may be the different 
testing methods, different amounts of administered EGCG, 
Fig. 3. AR/LV, AN/AR, and AN/LV as evaluated by triphenyltetra-
zolium chloride staining following 30 min regional ischemia and 2 
hrs reperfusion in isolated rat heart model. Rat hearts are treated 
with 1 (EGCG-1) or 10 μM (EGCG-10) of polyphenol (-)-epigallocat-
echin gallate (EGCG). EGCG-10 treated hearts signifi  cantly decrease 
AN/AR and AN/LV compared to EGCG-untreated hearts (EGCG-
0). AR: area at risk, AN: area of necrosis, LV: volume of left ventricle. 
Values are expressed as mean ± SEM. *P < 0.05 vs. EGCG-0.174 www.ekja.org
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and different administration times. However, the LVDP and 
RPP enhancements in the present study are similar to the 
results of Townsend et al. [12], where, during ischemia, they 
administered EGCG and stimulated LVDP recovery after 
reperfusion. EGCG administration, whether during ischemia or 
reperfusion, consequently enhances cardiac hemodynamics. 
However, in assessing the damage caused by cardiac ischemia 
and reperfusion, the cardiac hemodynamic indicies that refl  ect 
mechanical function may not be the suitable [17]. In evaluating 
reperfusion injury, measuring the degree of cardiac necrosis 
may be a more reliable indicator. 
    Most biological studies assessing EGCG used concentrations 
ranging from 10 μM to 100 μM. The present study observed 
the reduction of cardiac necrosis with administration of 10 μM. 
However, a human blood concentration of 10 μM EGCG can 
only be achieved if the subjects under fasting were to ingest 
50-60 cups of green tea. In addition, even by ingesting 800 
mg capsules of pure EGCG, it would be difficult to achieve a 
concentration greater than 5 μM [6]. Therefore, 10 μM EGCG, 
which proved to be effective in reducing cardiac necrosis, is 
impossible to achieve for human beings by just drinking green 
tea. Although not yet clinically feasible, therapeutic levels may 
be possible by intravenous administration. 
    Recently, there have been studies reporting that green tea has 
reduced the incidence of coronary artery disease and related 
deaths in human beings. Nakachi et al. [18] reported that 
drinking more than 10 cups of green tea reduced the likelihood 
of cardiovascular disease-related death. Sano et al. [19] reported 
that when patients undergoing coronary angiography were 
separated into groups with and without coronary occlusion, 
the group without coronary occlusion drank significantly 
much more green tea, about 6 glasses a day. Kuriyama [20] also 
showed in an epidemiological survey that drinking green tea 
reduced the risk of cardiovascular diseases. A long-term cohort 
study [21] on 40,000 subjects reported that green tea reduced 
death rates, especially deaths due to cardiovascular diseases. 
However, there are still no objective data on the exact amount of 
green tea needed to reduce the risk of cardiovascular diseases. 
However, it is unclear whether the effects of green tea may 
differ in relation to other factors such as race, culture, region, 
diabetes, hypertension, and hyperlipidemia. More research is 
required. 
    Th   e studies on whether EGCG reduces the rates of ischemia- 
and reperfusion-related damage in animals and human beings 
so far have not yet been able to explain the mechanisms 
behind reduction. Townsend et al. [12] suggested that the 
cardioprotective effect of EGCG is due to the reduction of 
phosphorylation and activation of pro-apoptotic factors, and 
the signal transduction and activator of transcription (STAT)-
1. Potenza et al. [22] stated that EGCG is cardioprotective, 
because it triggers the production of nitric oxide and activates 
phosphatidylinositol-3-OH kinase. Li et al. [15] believes that 
EGC, a green tea catechin, causes myocardial contraction due to 
protein kinase C epsilon. Although the activation of G protein-
coupled receptors (GPCR) is involved in the mechanism of 
intracellular messaging in the prevention of reperfusion injury 
[23], the relationship between EGCG and GPCR activation has 
yet to be illuminated. 
    Recent discoveries have illuminated the main mechanisms 
involved in the cardioprotective effect after reperfusion 
injury, which include the ERK1/2 or PI3-kinase as the main 
intracellular control pathway [24,25]. However, Dreger et al. 
[26] reported in their study using cardiac muscle cells, that the 
activation of prosurvival signaling kinases and the upregulation 
of antioxidative enzymes had no eff  ect on the cardioprotective 
activity of EGCG. Also, it has recently been discovered that 
during the first few minutes of reperfusion, the inhibition of 
the opening of the mitochondrial permeability transition pore 
(MPTP) is the final target of the cardioprotective mechanism 
of EGCG [27,28]. More detailed research on the intracellular 
control pathway of cardioprotection by EGCG, including the 
inhibition of the opening of MPTP is needed. 
    In conclusion, the results of this study show that EGCG, the 
primary bioactive substance of green tea, reduced reperfusion-
induced cardiac necrosis rates in isolated mouse hearts. In 
addition, EGCG administered during reperfusion reduced 
stunning after reperfusion. However, detailed research on the 
intracellular pathways involved in the prevention of cardiac 
reperfusion damage by EGCG and on whether green tea is 
effective in reducing cardiac reperfusion damage in human 
beings, is needed. 
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